Memo Therapeutics announces proof of concept of its antibody platform

A first series of human monoclonal antibodies against a viral antigen has been identified from a human donor-derived antibody repertoire (antibodyome) library using its huMemoMAB antibody discovery platform. “MEMO has now a best in class antibody discovery platform for discovery from human donors or patients, called huMemoMAB, and immunized rabbits, rbMemoMAB, respectively. This puts MEMO in a unique position for any antibody discovery program” CEO Armin Mäder said.

MEMO’s CSO Christoph Esslinger commented: “This result is a first step towards MEMO’s vision to build and exploit cognate human antibodyome libraries from clinically selected donors. We will use this technology for discovery of antibodies with therapeutic potential in a broad range of disease areas.”

This discovery project has been started through a Swiss Government sponsored CTI program of MEMO with leading Swiss Universities. It also involves three non-interventional clinical study protocols in which more than 70 patients and healthy donors have already been recruited for MEMO’s future antibody repertoire library.

MEMO is a preclinical startup and focuses on proprietary lead generation programs and collaborations with the biotech/pharma industry.

About MemoMABTM
MemoMAB is a single cell-based technology platform and the only technology to date that enables banking and expression screening of large authentic antibody repertoires (antibodyomes) of human and animal origin. It uses state of the art high throughput single cell technology for the rapid/fast processing of millions of antibody producing cells.

(Press release)

Picture: Kateryna Kon / Fotolia